Bruce Schackman

April 19, 2021 Research Highlight

Harmonizing Healthcare and Other Resource Measures for Evaluating Economic Costs in Substance Use Disorder Research

The National Institute on Drug Abuse, or NIDA, considers data harmonization in substance use disorder, human immunodeficiency virus (HIV), and hepatitis C virus (HCV) research a high-priority. Data harmonization allows investigators to synthesize data across independent studies and promote more rigorous and comparable analyses of an intervention, program, or policy. Harmonizing data also ensures that […]

November 9, 2020 Research Highlight

Dissemination Science to Advance the Use of Simulation Modeling

COVID-19 has brought simulation modeling to the foreground of public discourse, as policy makers and stakeholders project the effects of different interventions to “flatten the curve.” Simulation models allow investigators to tinker with different conditions of the world to observe how they affect future outcomes; however, translating the models’ results to the public can be […]

July 17, 2020 Collaborations

CHERISH Awarded Five-year Center of Excellence Grant to Continue Substance Use Health Economics Research

The National Institute on Drug Abuse (NIDA) of the National Institutes of Health has awarded the Center for Health Economics of Treatment Interventions for Substance Use, HCV and HIV (CHERISH) a five-year grant to continue the Center’s activities as a national center of excellence. CHERISH was founded in 2015 as a multi-institutional center for health […]

May 12, 2020 Policy Watch

COVID-19 Can Change The Way We Respond To The Opioid Crisis – For The Better

The Coronavirus (COVID-19) pandemic has brought unprecedented challenges in healthcare delivery to people who use drugs. However, it may also have provided impetus to precipitate innovative changes in providing opioid overdose prevention, syringe services, and medication for opioid use disorder (MOUD) to this vulnerable population. In a new Viewpoint in Psychiatric Services, CHERISH Research Affiliate Yuhua Bao from […]

May 6, 2020 Research Highlight

Simulation Modeling Presents Opportunities To Support The Public Health Response To The Opioid Crisis In North America

Although there are several evidence-based cost-effective interventions for people with opioid use disorder (OUD), they are underutilized. Questions remain regarding intervention selection, and cost of service delivery. Simulation modeling offers an opportunity to support decision making to address the syndemic of opioid overdose, HIV, and hepatitis C (HCV). In an article recently published in the International Journal […]

July 26, 2019 Collaborations

CHERISH Workshop Addresses an ‘Unfortunate Reality’ of the Addiction Treatment Industry

Funded by the National Institute on Drug Abuse and established in 2015, CHERISH is a five year collaboration of researchers from the Leonard Davis Institute of Health Economics (LDI) of the University of Pennsylvania, Weill Cornell Medical College, Boston Medical Center, and the University of Miami. Their work is focused on studying the health economics […]

June 3, 2019 Research Highlight

Buprenorphine for Opioid Use Disorder Lowers Overdose Risk in Commercially Insured Individuals

“Medications for opioid use disorder saves lives.” That’s the title and conclusion of a recent report by the National Academies of Sciences, Engineering and Medicine, based on a review of the scientific evidence. In a new study in Drug and Alcohol Dependence, CHERISH investigators Jake Morgan, Bruce Schackman and Benjamin Linas add to this evidence base by […]

April 19, 2019 Collaborations

NIH funds HEALing Communities Study in Four States

On April 18, the National Institute on Drug Abuse (NIDA) together with the Substance Abuse and Mental Health Services Administration (SAMHSA) announced research sites in four states will receive funding as part of the Helping to End Addiction Long-term (HEAL) Initiative HEALing Communities Study. Each state will engage stakeholders and researchers across 15 communities in their […]

February 21, 2019 Research Highlight

Naloxone Sales Likely to Increase after Switch to Over-the-Counter Status

Naloxone is an opioid antagonist rescue medication that reverses the effects of an opioid overdose, and thus a critical tool to prevent fatal opioid overdoses. CHERISH Investigators Drs. Sean Murphy, Jake Morgan, and Bruce Schackman, and CHERISH staff member Philip Jeng, MS predicted pharmacy sales following conversion of naloxone to over-the-counter (OTC) in a new […]

February 8, 2019 Research Highlight

Criminal Justice Measures for Economic Data Harmonization in Substance Use Disorder Research

The intersection of criminal justice-involved populations and people who use substances makes criminal justice outcomes particularly significant for estimating the economic impact of substance use disorder interventions. New National Institute on Drug Abuse (NIDA) HEAL initiative funding opportunities in response to the opioid crisis include integrated studies that will develop, test, and validate evidence-based approaches to preventing […]

December 18, 2018 Research Highlight

Cost and Cost-Effective Analyses of Buprenorphine Naloxone versus Injectable Naltrexone

One key strategy in reducing deaths from the opioid epidemic is to improve access to existing evidence-based treatments. Two new economic studies by CHERISH Investigators Drs. Sean Murphy, Kathryn McCollister, and Bruce Schackman can help providers, patients, and payers sort through alternative pharmacotherapies to prevent opioid relapse. The US Food and Drug Administration has approved […]

October 2, 2018 Research Highlight

Impact of State Policies for Prescription Drug Monitoring Programs on High-Risk Opioid Prescriptions

A recent study in Health Affairs by CHERISH Research Affiliate Dr. Yuhua Bao and CHERISH investigators Dr. Zachary Meisel and Dr. Bruce Schackman examined the impact of prescription drug monitoring program policies on high-risk opioid prescriptions. Prescription drug monitoring programs (PDMPs) are statewide databases of controlled substances dispensed at retail pharmacies. Currently, all states and Washington D.C. except Missouri […]

Engage with CHERISH

Submit a Consultation Request or Contact Us to learn more about how CHERISH can support your research or policy goals.